Developer docs
API playgroundTry for free, no card

Search company profiles

DEFTA Partners

Full company profile

uuid0002acj

Namestring
DEFTA Partners
Legal namestring
DEFTA Partners
Company typeenum
Private
Founded yearint
1980
Descriptiontext

DEFTA Partners is a privately held venture capital and private investment firm founded in the 1980s by George Hara and headquartered in San Francisco, with regional offices in Tokyo (Yokohama) and Hong Kong. The firm identifies, nurtures, and funds early-stage technology companies, focusing on three pillars: healthcare (advanced therapeutics, health ICT, and enabling technologies aimed at enabling healthy longevity), ICT under its "pervasive ubiquitous communications" (PUC) thesis (encompassing embedded devices, digital TV, and online security), and global investments that support portfolio companies scaling across North America, Europe, Asia, and the Middle East. DEFTA has invested in more than 100 companies since the 1980s across the U.S., U.K., Israel, Bangladesh, and Japan, with notable historical investments including the first gene therapy company (Viagene), the first antisense therapy company (Isis Pharmaceuticals), the first bioinformatics company (Arris Pharmaceuticals), and Fortinet (which went public in 2009).

The firm operates through DEFTA Capital, DEFTA Corporation, and DEFTA Healthcare Technologies, and maintains a strategic joint venture with BRAC (the world's largest NGO) to operate bracNet, an internet service provider in Bangladesh. Revenue is generated through equity investments in early-stage technology companies, with returns realized via exits such as IPOs (e.g., Fortinet, 2009) and M&A; pricing and investment terms are individually negotiated with portfolio companies and are not publicly disclosed. The firm does not develop or sell products itself; its "technology" is the proprietary PUC investment thesis and the global network that supports portfolio internationalization. The leadership team, anchored by Group Chairman & CEO George Hara, leverages Hara's senior advisory roles to Japan's government (Senior Advisor to the Minister of Finance, 2005-2009; Deputy Chairman of the Expert Panel on Economic and Fiscal Policy; Prime Minister's Special Commissioner on the Government Tax Panel) to source cross-border deal flow, particularly between the U.S. and Japan.

Short descriptiontext

DEFTA Partners is a privately held venture capital firm founded in the 1980s by George Hara, headquartered in San Francisco with offices in Tokyo and Hong Kong. It funds early-stage technology companies in healthcare (advanced therapeutics, health ICT) and ICT (pervasive ubiquitous communications) across 100+ investments globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital, early-stage investments, technology investing, healthcare investments, seed-stage funding
Product category
Venture Capital
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Capital Returns
TypeLicensing Royalties
Description

DEFTA Partners generates returns through equity investments in early-stage technology companies. The firm identifies and funds innovative companies with the goal of leading them to global success, with successful exits including first gene therapy company Viagene, first antisense therapy company Isis Pharmaceuticals, and first bioinformatics company Arris Pharmaceuticals.

deftapartners.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Infrastructure, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

DEFTA Partners is a venture capital firm that identifies, nurtures, and funds early-stage technology companies primarily in Healthcare (advanced therapeutics, health ICT, and enabling technologies) and ICT (pervasive ubiquitous communications model covering embedded devices, digital TV, and online security). The firm takes equity positions and provides hands-on global expertise to help portfolio companies scale internationally across North America, Europe, Asia, and the Middle East.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

DEFTA Partners is a venture capital firm, not a product company. The company identifies, nurtures, and funds early-stage technology companies. Their investment focus spans three main areas: Healthcare (advanced therapeutics, health ICT, and enabling technologies), ICT (pervasive ubiquitous communications model encompassing embedded devices, digital TV, and online security), and Global investments (with portfolio companies across North America, Europe, Asia, and the Middle East). The company has invested in more than 100 companies since the 1980s, with offices in San Francisco, Tokyo, and Hong Kong.

Product and service1 record
1Seed and Early-Stage Equity Investment
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1BRAC
Strategic tierCoreTypeStrategic or Co-development Partner
Description

DEFTA Partners works with BRAC, the world's largest NGO, in establishing and operating bracNet, an internet service provider in Bangladesh. This partnership demonstrates DEFTA's commitment to sustainable growth in developing markets and represents a core strategic alliance for expanding connectivity infrastructure.

deftapartners.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ARCH Venture Partners is a long-tenured early-stage venture capital firm that invests in life sciences, physical sciences, and information technology companies, often at company formation or seed stage. Directly comparable to DEFTA in stage focus (seed/first-round) and sector mix (healthcare + deep tech), with a similarly long track record of identifying category-defining science and technology companies.

TypeBroad incumbent
Description

Andreessen Horowitz (a16z) is a broad-based venture capital firm investing across stages and sectors with significant activity in early-stage technology and bio/healthcare. Comparable as an incumbent in the same early-stage technology and healthcare investing arena that DEFTA occupies, though much larger and more diversified across stages and geographies.

TypeDirect peer
Description

DCVC is an early-stage venture capital firm backing deep-tech and science-driven companies at the seed and Series A stages. Comparable to DEFTA's focus on pervasive ubiquitous communications, embedded devices, and advanced therapeutics with similarly conviction-driven early-stage capital deployment.

TypeDirect peer
Description

Founders Fund is a San Francisco-based venture capital firm that invests in early-stage technology companies across a range of frontier technology areas. Comparable to DEFTA in early-stage technology focus, San Francisco base, and orientation toward deep-technology and science-driven investments.

TypeBroad incumbent
Description

Bessemer Venture Partners is a long-tenured venture capital firm with a multi-stage approach and notable presence in early-stage technology and healthcare. Comparable to DEFTA's early-stage technology and healthcare focus, though BVP operates at much greater scale across more stages and geographies.

TypeBroad incumbent
Description

Kleiner Perkins is a long-established Silicon Valley venture capital firm with historic strength in early-stage technology and healthcare investing. Comparable to DEFTA as a long-tenured early-stage tech and healthcare investor, though Kleiner operates at significantly greater scale and brand visibility.

TypeDirect peer
Description

Lux Capital is an early-stage venture firm investing in emerging science and technology ventures at the intersection of science, health, and technology. Closely comparable to DEFTA's focus on advanced therapeutics, health ICT, and pervasive ubiquitous communications, with similar seed-to-Series A entry strategy and emerging-tech orientation.

TypeDirect peer
Description

Draper Associates is an early-stage venture capital firm focused on seed and Series A investments in technology companies with a global orientation. Directly comparable to DEFTA in stage (seed/first-round), sector (technology), and willingness to back emerging-market and cross-border technology plays.

TypeDirect peer
Description

Khosla Ventures is an early-stage venture firm investing across technology, sustainability, and healthcare with a high tolerance for risk and a willingness to fund unconventional ideas. Directly comparable to DEFTA in seed/first-round entry, healthcare-technology crossover focus, and pattern of identifying contrarian, first-in-category opportunities.

TypeBroad incumbent
Description

New Enterprise Associates is a large, multi-stage venture capital firm investing across technology and healthcare. Comparable to DEFTA in its dual focus on technology and healthcare, though NEA operates at significantly larger scale with a broader stage range and more institutional LP base.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment35 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DEFTA Partners

Venture Capitaldeftapartners.com

DEFTA Partners is a privately held venture capital firm founded in the 1980s by George Hara, headquartered in San Francisco with offices in Tokyo and Hong Kong. It funds early-stage technology companies in healthcare (advanced therapeutics, health ICT) and ICT (pervasive ubiquitous communications) across 100+ investments globally.

What DEFTA Partners does

DEFTA Partners is a privately held venture capital and private investment firm founded in the 1980s by George Hara and headquartered in San Francisco, with regional offices in Tokyo (Yokohama) and Hong Kong. The firm identifies, nurtures, and funds early-stage technology companies, focusing on three pillars: healthcare (advanced therapeutics, health ICT, and enabling technologies aimed at enabling healthy longevity), ICT under its "pervasive ubiquitous communications" (PUC) thesis (encompassing embedded devices, digital TV, and online security), and global investments that support portfolio companies scaling across North America, Europe, Asia, and the Middle East. DEFTA has invested in more than 100 companies since the 1980s across the U.S., U.K., Israel, Bangladesh, and Japan, with notable historical investments including the first gene therapy company (Viagene), the first antisense therapy company (Isis Pharmaceuticals), the first bioinformatics company (Arris Pharmaceuticals), and Fortinet (which went public in 2009).

The firm operates through DEFTA Capital, DEFTA Corporation, and DEFTA Healthcare Technologies, and maintains a strategic joint venture with BRAC (the world's largest NGO) to operate bracNet, an internet service provider in Bangladesh. Revenue is generated through equity investments in early-stage technology companies, with returns realized via exits such as IPOs (e.g., Fortinet, 2009) and M&A; pricing and investment terms are individually negotiated with portfolio companies and are not publicly disclosed. The firm does not develop or sell products itself; its "technology" is the proprietary PUC investment thesis and the global network that supports portfolio internationalization. The leadership team, anchored by Group Chairman & CEO George Hara, leverages Hara's senior advisory roles to Japan's government (Senior Advisor to the Minister of Finance, 2005-2009; Deputy Chairman of the Expert Panel on Economic and Fiscal Policy; Prime Minister's Special Commissioner on the Government Tax Panel) to source cross-border deal flow, particularly between the U.S. and Japan.

DEFTA Partners firmographics

Firmographics
Name
DEFTA Partners
Legal name
DEFTA Partners
Website
https://deftapartners.com
Company type
Private
Founded year
1980
Operating status
Operating
Headcount range
11–50 employees
Short description
DEFTA Partners is a privately held venture capital firm founded in the 1980s by George Hara, headquartered in San Francisco with offices in Tokyo and Hong Kong. It funds early-stage technology companies in healthcare (advanced therapeutics, health ICT) and ICT (pervasive ubiquitous communications) across 100+ investments globally.
Ownership category
akta.pro rank

Where DEFTA Partners is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

DEFTA Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Venture Capital Returns: DEFTA Partners generates returns through equity investments in early-stage technology companies. The firm identifies and funds innovative companies with the goal of leading them to global success, with successful exits including first gene therapy company Viagene, first antisense therapy company Isis Pharmaceuticals, and first bioinformatics company Arris Pharmaceuticals.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

DEFTA Partners product offering

Product offering

Core offering

DEFTA Partners is a venture capital firm that identifies, nurtures, and funds early-stage technology companies primarily in Healthcare (advanced therapeutics, health ICT, and enabling technologies) and ICT (pervasive ubiquitous communications model covering embedded devices, digital TV, and online security). The firm takes equity positions and provides hands-on global expertise to help portfolio companies scale internationally across North America, Europe, Asia, and the Middle East.

Product overview

DEFTA Partners is a venture capital firm, not a product company. The company identifies, nurtures, and funds early-stage technology companies. Their investment focus spans three main areas: Healthcare (advanced therapeutics, health ICT, and enabling technologies), ICT (pervasive ubiquitous communications model encompassing embedded devices, digital TV, and online security), and Global investments (with portfolio companies across North America, Europe, Asia, and the Middle East). The company has invested in more than 100 companies since the 1980s, with offices in San Francisco, Tokyo, and Hong Kong.

Differentiator

Problem solved

Functional benefit

Products and services

  • Seed and Early-Stage Equity Investment

Companies that use DEFTA Partners

Customer profile

Segments3 records

Ideal customer profiles1 record

DEFTA Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

DEFTA Partners partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BRACcoreStrategic or Co-development PartnerDEFTA Partners works with BRAC, the world's largest NGO, in establishing and operating bracNet, an internet service provider in Bangladesh. This partnership demonstrates DEFTA's commitment to sustainable growth in developing markets and represents a core strategic alliance for expanding connectivity infrastructure.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

DEFTA Partners competitors and assessment

Company assessment

Direct peers

  • ARCH Venture Partners: ARCH Venture Partners is a long-tenured early-stage venture capital firm that invests in life sciences, physical sciences, and information technology companies, often at company formation or seed stage. Directly comparable to DEFTA in stage focus (seed/first-round) and sector mix (healthcare + deep tech), with a similarly long track record of identifying category-defining science and technology companies.
  • DCVC (Data Collective): DCVC is an early-stage venture capital firm backing deep-tech and science-driven companies at the seed and Series A stages. Comparable to DEFTA's focus on pervasive ubiquitous communications, embedded devices, and advanced therapeutics with similarly conviction-driven early-stage capital deployment.
  • Founders Fund: Founders Fund is a San Francisco-based venture capital firm that invests in early-stage technology companies across a range of frontier technology areas. Comparable to DEFTA in early-stage technology focus, San Francisco base, and orientation toward deep-technology and science-driven investments.
  • Lux Capital: Lux Capital is an early-stage venture firm investing in emerging science and technology ventures at the intersection of science, health, and technology. Closely comparable to DEFTA's focus on advanced therapeutics, health ICT, and pervasive ubiquitous communications, with similar seed-to-Series A entry strategy and emerging-tech orientation.
  • Draper Associates: Draper Associates is an early-stage venture capital firm focused on seed and Series A investments in technology companies with a global orientation. Directly comparable to DEFTA in stage (seed/first-round), sector (technology), and willingness to back emerging-market and cross-border technology plays.
  • Khosla Ventures: Khosla Ventures is an early-stage venture firm investing across technology, sustainability, and healthcare with a high tolerance for risk and a willingness to fund unconventional ideas. Directly comparable to DEFTA in seed/first-round entry, healthcare-technology crossover focus, and pattern of identifying contrarian, first-in-category opportunities.

Broad incumbents

  • Andreessen Horowitz: Andreessen Horowitz (a16z) is a broad-based venture capital firm investing across stages and sectors with significant activity in early-stage technology and bio/healthcare. Comparable as an incumbent in the same early-stage technology and healthcare investing arena that DEFTA occupies, though much larger and more diversified across stages and geographies.
  • Bessemer Venture Partners: Bessemer Venture Partners is a long-tenured venture capital firm with a multi-stage approach and notable presence in early-stage technology and healthcare. Comparable to DEFTA's early-stage technology and healthcare focus, though BVP operates at much greater scale across more stages and geographies.
  • Kleiner Perkins: Kleiner Perkins is a long-established Silicon Valley venture capital firm with historic strength in early-stage technology and healthcare investing. Comparable to DEFTA as a long-tenured early-stage tech and healthcare investor, though Kleiner operates at significantly greater scale and brand visibility.
  • New Enterprise Associates (NEA): New Enterprise Associates is a large, multi-stage venture capital firm investing across technology and healthcare. Comparable to DEFTA in its dual focus on technology and healthcare, though NEA operates at significantly larger scale with a broader stage range and more institutional LP base.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

DEFTA Partners social profiles

Digital presence

DEFTA Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DEFTA Partners leadership team

Management profile

Number of profiles

Profiles11 records

DEFTA Partners subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

DEFTA Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DEFTA Partners M&A and investment

M&A and investment

M&A

Investments35 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DEFTA Partners

What does DEFTA Partners do?

DEFTA Partners is a venture capital firm that identifies, nurtures, and funds early-stage technology companies primarily in Healthcare (advanced therapeutics, health ICT, and enabling technologies) and ICT (pervasive ubiquitous communications model covering embedded devices, digital TV, and online security). The firm takes equity positions and provides hands-on global expertise to help portfolio companies scale internationally across North America, Europe, Asia, and the Middle East.

Is DEFTA Partners a public or private company?

DEFTA Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was DEFTA Partners founded?

DEFTA Partners was founded in 1980. It employs 11 to 50 people.

Where is DEFTA Partners based?

DEFTA Partners is headquartered in San Francisco, United States, in the North America region.

How does DEFTA Partners make money?

One revenue line is on record: venture Capital Returns.

Who are DEFTA Partners's main competitors?

Direct peers on record are ARCH Venture Partners, DCVC (Data Collective), Founders Fund, Lux Capital, Draper Associates and Khosla Ventures. Broad incumbents are Andreessen Horowitz, Bessemer Venture Partners, Kleiner Perkins and New Enterprise Associates (NEA).

Does DEFTA Partners have an API?

No public API is recorded for DEFTA Partners.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Startup BusinessLe università in campo per finanziare il deep tech a Hong KongHong Kong universities HKU and HKUST launched new deep-tech investment funds to support startups. HKU's fund, with DEFTA Partners, raised about half of its $160 million HKD target, while HKUST's fund uses spin-off proceeds. Both aim to bridge the gap between research and commercialization.Mirage NewsHKU Innovation Week Showcases 120+ BreakthroughsHKU hosted its 2026 Innovation Week main event, showcasing over 120 innovations and attracting more than 1,000 representatives. The event launched HKU SPARC and the first close of a HK$160 million joint fund with DEFTA Partners. It also presented inaugural HKU Impact Awards to four alumni and faculty.ZapierAegle, a Miami biotech startup, raises $6.5 million Series A roundMiami-based biotech startup Aegle Therapeutics has closed a $6.5 million Series A financing round led by investors including Tellus BioVentures and DEFTA Healthcare Technologies. The company, which has raised a total of $10.4 million, is developing AGLE-102, an extracellular vesicle therapy for dystrophic epidermolysis bullosa, and anticipates entering clinical trials in early 2021.PR NewswireAegle Therapeutics Announces $4M Financing to Fund Groundbreaking Stem Cell Exosome Clinical Trial to Treat Orphan Disease Dystrophic Epidermolysis BullosaAegle Therapeutics Corp., a Boston and Miami-based biotechnology company developing extracellular vesicle therapies, closed a $4 million financing round led by New World Angels with participation from Tellus BioVentures, DEFTA Healthcare Technologies, DeepWork Capital, and existing investors including OceanAzul Partners. The funding will support advancement of AGLE-102 into clinical trials for dystrophic epidermolysis bullosa, a rare pediatric skin blistering disorder, with the company's Investigational New Drug application already cleared by the FDA and trials expected to begin in the first half of 2020. Aegle's platform technology, based on intellectual property licensed from the University of Miami, uses exosomes secreted by allogeneic bone marrow-derived mesenchymal stem cells and has potential applications beyond dermatology.FinSMEsActuate Therapeutics Closes $21.7M Series B FinancingActuate Therapeutics raised $21.7M in Series B financing led by Kairos Ventures, with participation from DEFTA Partners, Tech Coast Angels, and existing investors. The company will use the funds to expand its Phase 1/2 clinical trial of 9-ING-41 and advance its pediatric neuroblastoma program.GlobeNewswireHarris & Harris Group Portfolio Company, ORIG3N, ClosesORIG3N closed a $12.5 million Series A financing led by Harris & Harris Group, with participation from Syno Capital, DEFTA Partners, and existing investors. The funds will support the launch of LifeSystems cellular models from its LifeCapsule bio-repository, which launched earlier this year.FinSMEs1World Online Completes $2.5M Series A2 Equity Financing - FinSMEs1World Online, a San Jose-based publisher engagement platform, completed a $2.5M Series A2 equity financing. Backers include DEFTA Partners, Altair Capital, GV Launch Gurus, and Nest HK. The company will use the funds to expand worldwide.